Maxygen Gets Approval for Clinical Trial of Factor VIIa in the UK.
HEALTH AND BEAUTY CLOSE-UP-13 June 2008-Maxygen Gets Approval for Clinical Trial of Factor VIIa in the UK(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Maxygen announced that it has filed a Clinical Trial Authorization (CTA) and received the necessary approvals in the United Kingdom to initiate a first-in-human Phase I...

All in the family: for some animals, the ideal mate is a brother, sister or cousin.
In late March, as winter unclenches its frigid grip on upstate New York, a spotted salamander's thoughts turn fleetingly to love. After early spring rains soak the forests where the salamanders live, thousands of the slimy little creatures descend on small vernal pools for the amphibian equivalent of an...

Wyeth and Progenics Secure Marketing Approval from European Commission for Relistor.
HEALTH AND BEAUTY CLOSE-UP-7 July 2008-Wyeth and Progenics Secure Marketing Approval from European Commission for Relistor(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Wyeth Pharmaceuticals, a division of Wyeth, and Progenics Pharmaceuticals announced that the companies have received marketing approval for Relistor (methylnaltrexone bromide) subcutaneous injection from the European Commission....

Baxter Declares Quarterly Dividend.
HEALTH AND BEAUTY CLOSE-UP-12 February 2008-Baxter Declares Quarterly Dividend(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com The Board of Directors of Baxter International Inc. has declared a quarterly dividend of $0.2175 per share of Baxter common stock. The company noted that the payment represents a continuation of the...

Baxter International Sets Date for Second Quarter Financial Results Conference Call.
HEALTH AND BEAUTY CLOSE-UP-29 June 2008-Baxter International Sets Date for Second Quarter Financial Results Conference Call(C)2008 - CloseUpMedia - newsdesk@closeupmedia.com Baxter International will host a quarterly conference call to discuss its second quarter 2008 financial results on Thursday, July 17, at 8:30 a.m. Eastern Time (7:30 a.m....

Baxter posts first-quarter earnings gain of 6%.
Earnings at Baxter International Inc. jumped 6% in the first quarter of this year, prompting the company to raise its 2008 outlook. Deerfield, IL-based Baxter reported net income of $429 million, or 67 cents per share, compared with $403 million, or 61 cents per share, in the...

Mother knows all: next generation of prenatal tests finds clues to baby's health in mother's blood.
For 9 months, doctors can at best make educated guesses about a growing fetus' future as a healthy human. Those first fuzzy black-and-white ultrasound images can provide a mother with the peace of mind that she has a boy or girl with a beating heart, but many developmental maladies...

Alphanate.
Alphanate (Antihemophilic Factor/von Willebrand Factor Complex [Human], Grifols Biologicals) This clotting factor concentrate is the first biologic product approved for patients with von Willebrand disease (vWD) who are undergoing surgery or invasive procedures and for whom desmopressin is either ineffective or contraindicated, according to the...

Sports participation desirable for kids with chronic conditions.
QUEBEC CITY -- Children with chronic health conditions should be encouraged to participate in sports, and soon there will be guidelines about physical activity in children with specific conditions, according to Dr. John Philpott, who is heading the joint effort of the Canadian Academy of Sport Medicine and the...

Hemofilia: diagnostico molecular y alternativas de tratamiento.
RESUMEN La hemofilia es una enfermedad recesiva ligada al cromosoma X que generalmente padecen los hombres. El diagnóstico genético preimplantación (DGP), el diagnóstico prenatal y el diagnóstico molecular de las mutaciones que causan hemofilia, se realizan en investigaciones aisladas con el fin de hacer prevención primaria, asesorar...